These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38134746)

  • 41. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
    Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.
    Chatterjee P; Karn R; Isaac AE; Ray S
    Clin Transl Oncol; 2023 Nov; 25(11):3057-3072. PubMed ID: 37079210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.
    Wang P; Zhu WT; Wang Y; Song SS; Xi Y; Yang XY; Shen YY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Miao ZH; Zhang A; He JX
    Eur J Med Chem; 2023 Nov; 259():115709. PubMed ID: 37567056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing.
    Asai T; Yokota M; Isomura H; Koide H; Sakurai N; Okamoto A; Ando H; Dewa T; Oku N
    J Pharm Sci; 2023 Jul; 112(7):1908-1914. PubMed ID: 36828124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    Layman RM; Arun B
    Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    Shi Y; Jin J; Wang X; Ji W; Guan X
    Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
    De Summa S; Pinto R; Pilato B; Sambiasi D; Porcelli L; Guida G; Mattioli E; Paradiso A; Merla G; Micale L; De Nittis P; Tommasi S
    Cell Death Dis; 2014 Feb; 5(2):e1076. PubMed ID: 24556691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    Guney Eskiler G; Ozman Z; Haciefendi A; Cansaran-Duman D
    Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1031-1041. PubMed ID: 36598514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
    Li J; Lan M; Peng J; Xiong Q; Xu Y; Yang Y; Zhou Y; Liu J; Zeng Z; Yang X; Zhang Z; Zhang P; Zhu Q; Wu W
    Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
    Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.